Citations

Clear

4847 citation(s) found for "Yu, Eric".

Virtual pelvic anatomy simulator improved medical student comprehension of pelvic anatomy
Hassinger, James Peyton, Dozois, Eric J. , Pawlina, Wojciech, Pendlimari, Rajesh, Fidler, Jeff, Holmes, David R. , Robb, Richard A., Holubar, Stefan D.

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.825.3 Get It

Given curricular time constraints, the complex relationships of pelvic viscera can be difficult for students to master. We developed an interactive 3‐dimensional virtual pelvic model using high‐resolution 3‐Telsa magnetic resonance and 64‐slice computed tomographic datasets of a healthy male. The aim of this study was to determine if use of this curricular adjunct was associated with improved comprehension of pelvic anatomy as measured by a 33 item test. The software was distributed to 47 first year medical students during their 3‐day pelvic anatomy curriculum. Forty students (85%) completed the test. Students used the software for a median of 15 (interquartile range [IQR] 10 – 22) minutes; total minutes studying pelvic anatomy was 240 (IQR 125 – 525) minutes. Minutes of software use was strongly associated with the total study time (p<0.0001). On univariate analysis, pelvic anatomy test scores were associated with both minutes of software use (p=0.05) and total study time (p=0.04). On multivariate analysis both software use (p=0.12) and total study time (p=0.08) trended towards significant association with test scores. Most students used the software alongside books to aid in initial spatial orientation to the pelvis. Virtual anatomy software can be a valuable, effective adjunct to traditional anatomy education. Source of funding: Mayo Foundation for Medical Education and Research. Grant Funding Source : Source of funding: Mayo Foundation for Medical Education and Research.
Evidence that hypoxia‐induced pulmonary vasoconstriction in humans is primarily a post‐capillary event
Taylor, Bryan Joseph, Snyder, Eric M., Olson, Thomas P. , O’Malley, Kathy A., Johnson, B. A. , Johnson, Bruce

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 24 | Issue: S1 | Pages: No page available

10.1096/fasebj.24.1_supplement.990.8 Get It

Background Exposure to hypoxia causes pulmonary vasoconstriction (HPV) and may contribute to the pathogenesis of HAPE. The site of HPV, however, is controversial. While the majority of data suggests HPV occurs in the pulmonary arterioles (precapillary), there is evidence that HPV may also occur in postcapillary vessels. Expansion of pulmonary capillary blood volume (Vc) is primarily passive and thus closely linked to cardiac output (Q). Purpose To examine relationships between Q and Vc during exposure to hypoxia and fluid loading. Methods/Results Healthy adults (n=25, age=31±2 yr) reported to the lab for 2 exposures: 1) 17‐h 12.5% F I O 2 in a hypoxia tent, and 2) fluid loading using IV saline (30 ml/kg over ~15 min). Q, Vc and Dm (alveolar‐capillary conductance) were measured using a rebreathe method with small amounts of C 2 H 2 , CO and NO gas. Saline infusion caused an increase in Q (32±6%, P <0.01) and Vc (39±13%, P <0.05), and a decrease in Dm (−9±3%, P <0.05). Vc/Q was not different pre‐ vs post‐saline (17±2 vs 18±3, P =0.40). Hypoxic exposure caused an increase in pulmonary arterial pressure (67±11%, P <0.01), Vc (57±20%, P =0.04) and Dm (35±6%, P <0.01) despite no change in Q (0.2±2.8%, P =0.98). Vc/Q was greater post‐ vs. pre‐hypoxia (24±4 vs. 17±2, P =0.06). Conclusion The rise in Vc with a constant Q during hypoxic exposure suggests a post capillary site for HPV causing the expansion of the pulmonary capillary bed. HL71478.
Super-Refractory Status Epilepticus in Children: A Retrospective Cohort Study
Vasquez, Alejandra , Farias‐Moeller, Raquel , Sánchez-Fernández, Iván, Amengual‐Gual, Marta , Anderson, Anne E. , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sands, Tristan T. , Sannagowdara, Kumar , Tasker, Robert C. , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Brenton, J Nicholas , Tasker, Robert C , Wainwright, Mark S , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Abend, Nicholas S. , Arya, Ravindra , Glauser, Tracy A. , Guerriero, Rejean M , Lai, Yi‐Chen , Novotny, Edward J. , Tchapyjnikov, Dmitry , Loddenkemper, Tobias

Mayo Clinic

Pediatric Critical Care Medicine | June 14, 2021 | Volume: 22 | Issue: 12 | Pages: e613-e625

10.1097/pcc.0000000000002786 | PMID 34120133 Get It

OBJECTIVES: To characterize the pediatric super-refractory status epilepticus population by describing treatment variability in super-refractory status epilepticus patients and comparing relevant clinical characteristics, including outcomes, between super-refractory status epilepticus, and nonsuper-refractory status epilepticus patients. DESIGN: Retrospective cohort study with prospectively collected data between June 2011 and January 2019. SETTING: Seventeen academic hospitals in the United States. PATIENTS: We included patients 1 month to 21 years old presenting with convulsive refractory status epilepticus. We defined super-refractory status epilepticus as continuous or intermittent seizures lasting greater than or equal to 24 hours following initiation of continuous infusion and divided the cohort into super-refractory status epilepticus and nonsuper-refractory status epilepticus groups. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We identified 281 patients (157 males) with a median age of 4.1 years (1.3–9.5 yr), including 31 super-refractory status epilepticus patients. Compared with nonsuper-refractory status epilepticus group, super-refractory status epilepticus patients had delayed initiation of first nonbenzodiazepine-antiseizure medication (149 min [55–491.5 min] vs 62 min [33.3–120.8 min]; p = 0.030) and of continuous infusion (495 min [177.5–1,255 min] vs 150 min [90–318.5 min]; p = 0.003); prolonged seizure duration (120 hr [58–368 hr] vs 3 hr [1.4–5.9 hr]; p < 0.001) and length of ICU stay (17 d [9.5–40 d] vs [1.8–8.8 d]; p < 0.001); more medical complications (18/31 [58.1%] vs 55/250 [22.2%] patients; p < 0.001); lower return to baseline function (7/31 [22.6%] vs 182/250 [73.4%] patients; p < 0.001); and higher mortality (4/31 [12.9%] vs 5/250 [2%]; p = 0.010). Within the super-refractory status epilepticus group, status epilepticus resolution was attained with a single continuous infusion in 15 of 31 patients (48.4%), two in 10 of 31 (32.3%), and three or more in six of 31 (19.4%). Most super-refractory status epilepticus patients (30/31, 96.8%) received midazolam as first choice. About 17 of 31 patients (54.8%) received additional treatments. CONCLUSIONS: Super-refractory status epilepticus patients had delayed initiation of nonbenzodiazepine antiseizure medication treatment, higher number of medical complications and mortality, and lower return to neurologic baseline than nonsuper-refractory status epilepticus patients, although these associations were not adjusted for potential confounders. Treatment approaches following the first continuous infusion were heterogeneous, reflecting limited information to guide clinical decision-making in super-refractory status epilepticus.
Natural History of Growing Sporadic Vestibular Schwannomas During Observation: An International Multi-Institutional Study
Marinelli, John P. , Carlson, Matthew L. , Nassiri, Ashley M. , Haynes, David S. , Link, Michael J. , Lohse, Christine M. , Reznitsky, Martin , Stangerup, Sven‐Eric, Cayé‐Thomasen, Per , Hunter, Jacob B.

Mayo Clinic

Otology & Neurotology | June 13, 2021 | Volume: 42 | Issue: 8 | Pages: e1118-e1124

10.1097/mao.0000000000003224 | PMID 34121081 Get It

Objective: Active treatment of small- or medium-sized vestibular schwannoma during wait-and-scan management is currently recommended at most centers globally once growth is detected. The primary aim of the current study was to characterize the natural history of growing sporadic vestibular schwannoma during observation. Study Design: Cohort study. Setting: Four tertiary referral centers across the United States and Denmark. Patients: Patients with two prior MRI scans demonstrating ≥2 mm of linear growth who continued observational management. Intervention: Observation with serial imaging. Main Outcome Measure: Subsequent linear growth-free survival (i.e., an additional ≥2 mm of growth) following initial growth of ≥2 mm from tumor size at diagnosis. Results: Among 3,402 patients undergoing observation, 592 met inclusion criteria. Median age at initial growth was 66 years (IQR 59–73) for intracanalicular tumors (N = 65) and 62 years (IQR 54–70) for tumors with cerebellopontine angle extension (N = 527). The median duration of MRI surveillance following initial detection of tumor growth was 5.2 years (IQR 2.4–6.9) for intracanalicular tumors and 1.0 year (IQR 1.0–3.3) for cerebellopontine angle tumors. For intracanalicular tumors, subsequent growth-free survival rates (95% CI; number still at risk) at 1, 2, 3, 4, and 5 years following the initial MRI that demonstrated growth were 77% (67–88; 49), 53% (42–67; 31), 46% (35–60; 23), 34% (24–49; 17), and 32% (22–47; 13), respectively. For cerebellopontine angle tumors, subsequent growth-free survival rates were 72% (68–76; 450), 47% (42–52; 258), 32% (28–38; 139), 26% (21–31; 82), and 22% (18–28; 57), respectively. For every 1 mm increase in magnitude of growth from diagnosis to tumor size at detection of initial growth, the HRs associated with subsequent growth were 1.64 (95% CI 1.25–2.15; p < 0.001) for intracanalicular tumors and 1.08 (95% CI 1.01–1.15; p = 0.02) for cerebellopontine angle tumors. Conclusions: Growth detected during observation does not necessarily portend future growth, especially for slowly growing tumors. Because early treatment does not confer improved long-term quality of life outcomes, toleration of some growth during observation is justifiable in appropriately selected cases.
Cardiac surgeons' concerns, perceptions, and responses during the COVID‐19 pandemic
Luc, Jessica G.Y. , Ad, Niv , Nguyen, Tom C. , Collaborators, the COVID‐19 North American Cardiac Surgery Survey Working Group, Arora, Rakesh C. , Bender, Edward M. , Bethencourt, Daniel M., Bisleri, Gianluigi , Boyd, Douglas, Chu, Michael , Cruz, Kim I. de la , DeAnda, Abe , Farkas, Emily A. , Fedoruk, Lynn M., Fiocco, Michael, Forcillo, Jessica , Fradet, Guy, Gammie, James S. , Geirsson, Arnar , Gerdisch, Marc , Girard, Leonard N., Kaiser, Clayton A., Khabbaz, Kamal R. , Khoynezhad, Ali , Kiaii, Bob, Légaré, Jean‐François , Lehr, Eric J. , MacArthur, Roderick, McCarthy, Patrick M. , Mehall, John R., Merrill, Walter H. , Moon, Marc R. , Ouzounian, Maral , Peltz, Matthias , Perrault, Louis P. , Preventza, Ourania , Ramchandani, Mahesh, Ramlawi, Basel , Salenger, Rawn , Sekela, Michael , Stulak, John M., Sutter, Francis P., Timek, Tomasz A. , Whitman, Glenn, Williams, Judson B., Yanagawa, Bobby , Ye, Jian , Zeigler, Sanford , Bisleri, Gianluigi , Forcillo, Jessica , Fremes, Stephen E , Geirsson, Arnar , Gerdisch, Marc W , Girard, Leonard N , Legare, Jean-Francois , Moon, Marc R , Preventza, Ourania , Yanagawa, Bobby , Ye, Jian , Arora, Rakesh , Chu, Michael W A , Collaborators, the COVID‐19 North American Cardiac Surgery Survey Working Group, Balkhy, Husam H. , Boyd, Douglas, Engelman, Daniel T. , Fremes, Stephen E. , Kaneko, Tsuyoshi , Kent, William D. T. , Lee, Richard , Sellke, Frank W. , Wong, Daniel R.

Mayo Clinic

Journal of Cardiac Surgery | June 12, 2021 | Volume: 36 | Issue: 9 | Pages: 3040-3051

10.1111/jocs.15681 | PMID 34118080 Get It

Impact of Cancer and Cardiovascular Disease on In-Hospital Outcomes of COVID-19 Patients: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry
Tehrani, David M. , Wang, Xiaoyan , Rafique, Asim , Herrmann, Joerg , Neilan, Tomas G. , Desai, Pooja , Parikh, Rushi V. , Hayek, Salim S. , Morgans, Alicia K. , Lopez‐Mattei, Juan , Yang, Eric H.

Mayo Clinic

No container title available | June 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-600795/v1 | PMID 34127966 Get It

Abstract Background: While pre-existing cardiovascular disease (CVD) appears to be associated with poor outcomes in patients with Coronavirus Disease 2019 (COVID-19), data on patients with CVD and concomitant cancer is limited. Evaluate the effect of underlying CVD and CVD risk factors with cancer history on in-hospital mortality in those with COVID-19.Methods: Data from symptomatic adults hospitalized with COVID-19 at 86 hospitals in the US enrolled in the American Heart Association’s COVID-19 CVD Registry was analyzed. The primary exposure was cancer history. The primary outcome was in-hospital death. Multivariable logistic regression models were adjusted for demographics, CVD risk factors, and CVD. Interaction between history of cancer with concomitant CVD and CVD risk factors were tested.Results: Among 8222 patients, 892 (10.8%) had a history of cancer and 1501 (18.3%) died. Cancer history had significant interaction with CVD risk factors of age, body mass index (BMI), and smoking history, but not underlying CVD itself. History of cancer was significantly associated with increased in-hospital death (among average age and BMI patients, adjusted odds ratio [aOR]=3.60, 95% confidence interval [CI]: 2.07-6.24; p<0.0001 in those with a smoking history and aOR=1.33, 95%CI: 1.01 - 1.76; p=0.04 in non-smokers). Among the cancer subgroup, prior use of chemotherapy within 2 weeks of admission was associated with in-hospital death (aOR=1.72, 95%CI: 1.05-2.80; p=0.03). Underlying CVD demonstrated a numerical but statistically nonsignificant trend toward increased mortality (aOR=1.18, 95% CI: 0.99 - 1.41; p=0.07).Conclusion: Among hospitalized COVID-19 patients, cancer history was a predictor of in-hospital mortality. Notably, among cancer patients, recent use of chemotherapy, but not underlying CVD itself, was associated with worse survival. These findings have important implications in cancer therapy considerations and vaccine distribution in cancer patients with and without underlying CVD and CVD risk factors.
Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial
Kudva, Yogish C. , Laffel, Lori M. , Brown, Sue A. , Raghinaru, Dan, Pinsker, Jordan E. , Ekhlaspour, Laya , Messer, Laurel H. , Kovatchev, Boris , Lum, John W. , Gonder‐Frederick, Linda , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Buckingham, Bruce A. , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Eggerman, Thomas L., Messer, Laurel H , Lum, John , Forlenza, Gregory P , Kovatchev, Boris , Buckingham, Bruce , Levy, Carol J. , Beck, Roy W. , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Doyle, Francis J. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | June 11, 2021 | Volume: 23 | Issue: 10 | Pages: 673-683

10.1089/dia.2021.0089 | PMID 34115959 Get It

Background: Closed-loop control (CLC) has been shown to improve glucose time in range and other glucose metrics; however, randomized trials >3 months comparing CLC with sensor-augmented pump (SAP) therapy are limited. We recently reported glucose control outcomes from the 6-month international Diabetes Closed-Loop (iDCL) trial; we now report patient-reported outcomes (PROs) in this iDCL trial. Methods: Participants were randomized 2:1 to CLC ( N = 112) versus SAP ( N = 56) and completed questionnaires, including Hypoglycemia Fear Survey, Diabetes Distress Scale (DDS), Hypoglycemia Awareness, Hypoglycemia Confidence, Hyperglycemia Avoidance, and Positive Expectancies of CLC (INSPIRE) at baseline, 3, and 6 months. CLC participants also completed Diabetes Technology Expectations and Acceptance and System Usability Scale (SUS). Results: The Hypoglycemia Fear Survey Behavior subscale improved significantly after 6 months of CLC compared with SAP. DDS did not differ except for powerless subscale scores, which worsened at 3 months in SAP. Whereas Hypoglycemia Awareness and Hyperglycemia Avoidance did not differ between groups, CLC participants showed a tendency toward improved confidence in managing hypoglycemia. The INSPIRE questionnaire showed favorable scores in the CLC group for teens and parents, with a similar trend for adults. At baseline and 6 months, CLC participants had high positive expectations for the device with Diabetes Technology Acceptance and SUS showing high benefit and low burden scores. Conclusion: CLC improved some PROs compared with SAP. Participants reported high benefit and low burden with CLC. Clinical Trial Identifier: NCT03563313.
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Nakamura, Ryotaro , Saber, Wael , Martens, Michael J. , Ramirez, Alyssa, Scott, Bart L. , Oran, Betül , Leifer, Eric , Tamari, Roni , Mishra, Asmita , Maziarz, Richard T. , Westervelt, Peter, Vasu, Sumithira , Patnaik, Mrinal M. , Kamble, Rammurti T., Forman, Stephen J. , Appelbaum, Frederick R. , Mendizabal, Adam , Logan, Brent R. , Horowitz, Mary M. , Scott, Bart , McGuirk, Joseph , Patnaik, Mrinal , Sekeres, Mikkael A , Logan, Brent , Horowitz, Mary , Cutler, Corey S. , Maziarz, Richard Thomas , Martens, Michael J , Oran, Betul , McGuirk, Joseph P. , Sekeres, Mikkael A.

Mayo Clinic

Journal of Clinical Oncology | June 9, 2021 | Volume: 39 | Issue: 30 | Pages: 3328-3339

10.1200/jco.20.03380 | PMID 34106753 Get It

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older patients with higher-risk MDS have not been defined. METHODS We conducted a multicenter biologic assignment trial comparing reduced-intensity HCT to hypomethylating therapy or best supportive care in subjects 50-75 years of age with intermediate-2 or high-risk de novo MDS. The primary outcome was overall survival probability at 3 years. Between January 2014 and November 2018, we enrolled 384 subjects at 34 centers. Subjects were assigned to the Donor or No-Donor arms according to the availability of a matched donor within 90 days of study registration. RESULTS The median follow-up time for surviving subjects was 34.2 months (range: 2.3-38 months) in the Donor arm and 26.9 months (range: 2.4-37.2 months) in the No-Donor arm. In an intention-to-treat analysis, the adjusted overall survival rate at 3 years in the Donor arm was 47.9% (95% CI, 41.3 to 54.1) compared with 26.6% (95% CI, 18.4 to 35.6) in the No-Donor arm ( P = .0001) with an absolute difference of 21.3% (95% CI, 10.2 to 31.8). Leukemia-free survival at 3 years was greater in the Donor arm (35.8%; 95% CI, 29.8 to 41.8) compared with the No-Donor arm (20.6%; 95% CI, 13.3 to 29.1; P = .003). The survival benefit was seen across all subgroups examined. CONCLUSION We observed a significant survival advantage in older subjects with higher-risk MDS who have a matched donor identified and underwent reduced-intensity HCT, when compared with those without a donor. HCT should be included as an integral part of MDS management plans in fit older adults with higher-risk MDS.
Announcing the Editorial Board Fellowship Program of the American Journal of Physiology-Lung Cellular and Molecular Physiology
Shimoda, Larissa A. , Bai, Chunxue , Bartlett, Nathan W. , Bastarache, Julie A. , Kuebler, Wolfgang M. , Prakash, Y. S. , Schmidt, Eric P. , Morty, Rory E. , Prakash, Y S , Feghali‐Bostwick, Carol A.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | June 9, 2021 | Volume: 321 | Issue: 1 | Pages: L116-L118

10.1152/ajplung.00239.2021 Get It

Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score
Gao, Chi , Polley, Eric C. , Hart, Steven N. , Huang, Hongyan , Lilyquist, Jenna , Boddicker, Nicholas , Na, Jie , Ambrosone, Christine B. , Auer, Paul L. , Gaudet, Mia M. , Haiman, Christopher A. , Jacobs, Eric J. , John, Esther M. , Lindström, Sara , Ma, Huiyan , Ong, Irene M. , Patel, Alpa V. , Taylor, Jack A. , Vachon, Celine M. , Weitzel, Jeffrey N. , Goldgar, David E. , Nathanson, Katherine L. , Chen, Chen , Hu, Chunling , Gnanaolivu, Rohan , Lilyquist, Jenna , Boddicker, Nicholas J , Na, Jie , Ambrosone, Christine B , Bernstein, Leslie , Burnside, Elizabeth S , Gaudet, Mia M , John, Esther M , Neuhausen, Susan L. , Newcomb, Polly A. , Ong, Irene M , Palmer, Julie R , Sandler, Dale P , Taylor, Jack A , Teras, Lauren R , Trentham-Dietz, Amy , Yao, Song , Weitzel, Jeffrey N , Goldgar, David E , Domchek, Susan M , Nathanson, Katherine L , Couch, Fergus J. , Kraft, Peter , Chen, C , Hart, Steven N , Polley, Eric C , Hu, Chunling , Bernstein, Leslie , Burnside, Elizabeth S. , Eliassen, A. Heather , Hunter, David J. , O’Brien, Katie M. , Olson, Janet E. , Palmer, Julie R. , Sandler, Dale P. , Tamimi, Rulla M. , Teras, Lauren R. , Trentham‐Dietz, Amy , Vachon, Celine M. , Weinberg, Clarice R. , Yao, Song , Domchek, Susan M. , Couch, Fergus J. , Kraft, Peter

Mayo Clinic

Journal of Clinical Oncology | June 8, 2021 | Volume: 39 | Issue: 23 | Pages: 2564-2573

10.1200/jco.20.01992 | PMID 34101481 Get It

PURPOSE This study assessed the joint association of pathogenic variants (PVs) in breast cancer (BC) predisposition genes and polygenic risk scores (PRS) with BC in the general population. METHODS A total of 26,798 non-Hispanic white BC cases and 26,127 controls from predominately population-based studies in the Cancer Risk Estimates Related to Susceptibility consortium were evaluated for PVs in BRCA1, BRCA2, ATM, CHEK2, PALB2, BARD1, BRIP1, CDH1, and NF1. PRS based on 105 common variants were created using effect estimates from BC genome-wide association studies; the performance of an overall BC PRS and estrogen receptor–specific PRS were evaluated. The odds of BC based on the PVs and PRS were estimated using penalized logistic regression. The results were combined with age-specific incidence rates to estimate 5-year and lifetime absolute risks of BC across percentiles of PRS by PV status and first-degree family history of BC. RESULTS The estimated lifetime risks of BC among general-population noncarriers, based on 10th and 90th percentiles of PRS, were 9.1%-23.9% and 6.7%-18.2% for women with or without first-degree relatives with BC, respectively. Taking PRS into account, more than 95% of BRCA1, BRCA2, and PALB2 carriers had > 20% lifetime risks of BC, whereas, respectively, 52.5% and 69.7% of ATM and CHEK2 carriers without first-degree relatives with BC, and 78.8% and 89.9% of those with a first-degree relative with BC had > 20% risk. CONCLUSION PRS facilitates personalization of BC risk among carriers of PVs in predisposition genes. Incorporating PRS into BC risk estimation may help identify > 30% of CHEK2 and nearly half of ATM carriers below the 20% lifetime risk threshold, suggesting the addition of PRS may prevent overscreening and enable more personalized risk management approaches.